Abstract 5400: QLS2313, a CD79b/CD20 tri-specific T cell engager with dual-targeting strategy developed as a new therapeutics for the treatment of DLBCL.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Ting Lu, Liuqing Yang, Fujia Yao, Dongdong Wu, Shuyong Zhao, Hua Ying, Weikang Tao
Institution: Qilu Pharmaceutical Co., Ltd. (China)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148787240